Medifast (MED) Accounts Payables (2010 - 2026)

Medifast has reported Accounts Payables for 17 years, with the latest figure at $38.3 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables fell 26.15% year-over-year to $38.3 million; the trailing twelve-month figure through Mar 2026 stood at $38.3 million (down 26.15% YoY), and the FY2025 full-year result was $38.4 million, down 32.1% from the prior year.
• Accounts Payables for Q1 2026 stood at $38.3 million, roughly flat from $38.4 million in the prior quarter.
• The five-year high for Accounts Payables was $174.4 million in Q1 2022, with the low at $38.3 million in Q1 2026.
• Historically, Accounts Payables has averaged $87.8 million across 5 years, with a median of $71.2 million in 2024.
• Annual changes were most pronounced in 2022 — Accounts Payables grew 23.45% — and 2025, when it tumbled 41.78%.
• Medifast's Accounts Payables stood at $134.7 million in 2022, then slumped by 35.84% to $86.4 million in 2023, then sank by 34.62% to $56.5 million in 2024, then tumbled by 32.1% to $38.4 million in 2025, then fell by 0.25% to $38.3 million in 2026.
• The last three Accounts Payables figures came in at $38.3 million (Q1 2026), $38.4 million (Q4 2025), and $41.2 million (Q3 2025), per Business Quant data.